文献速递慢性静脉疾病

机械化学消融与射频消融治疗大隐静脉功能不全的多中心随机对照试验两年结果(MARADONA试验)

Two-year results of a multicenter randomized controlled trial comparing Mechanochemical endovenous Ablation to RADiOfrequeNcy Ablation in the treatment of primary great saphenous vein incompetence (MARADONA trial).
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2019-01-01

MARADONA多中心随机对照试验比较机械化学消融(MOCA)与射频消融(RFA)治疗原发性大隐静脉功能不全,共213例患者随机、209例治疗。

要点

  • MOCA术后短期疼痛较轻、VCSS改善更快,但色素沉着发生率更高。
  • MOCA的1年解剖成功率低于RFA,主要由部分再通驱动,2年时完全失败数无差异。
  • 1年和2年临床成功率及疾病特异性生活质量在两种技术间相似。

核心结论

  • 单侧MOCA短期术后疼痛较RFA轻但色素沉着更多,VCSS改善更快。
  • MOCA解剖失败更多,主要为部分再通,但1年和2年临床结局与RFA相似。

研究设计与样本

  • 多中心前瞻性随机对照试验,比较MOCA与RFA治疗大隐静脉功能不全。
  • 共213例患者随机(为计划数的46.3%),209例接受治疗(MOCA组105例,RFA组104例)。
  • 因报销暂停而提前终止入组。

关键数值与推荐

  • 2年随访完全失败数无差异;RFA组1年双功超声发现1例深静脉血栓,无临床后遗症。
  • 严重不良事件:MOCA组1例室颤(1年),RFA组1例不稳定型心绞痛(2年)。

临床怎么用

  • MOCA可作为RFA的替代选择,尤其适合关注术后疼痛的患者。
  • 需告知患者MOCA色素沉着及部分再通导致解剖失败的风险较高。
  • 两种技术1年和2年临床成功率及生活质量相似,选择可个体化。

局限性

  • 入组提前终止,样本量仅为计划数的46.3%。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Endothermal techniques have proved to be effective for treatment of incompetent truncal veins. The tumescentless mechanochemical ablation (MOCA) technique has become an alternative treatment modality, but its outcome with regard to endothermal techniques is still unclear. METHODS: A multicenter prospective randomized controlled trial was designed comparing MOCA with radiofrequency ablation (RFA) to treat great saphenous vein incompetence with the hypothesis that MOCA is associated with less postprocedural pain and a comparable anatomic and clinical success rate at 1-year follow-up. Disease-specific quality of life and general health-related quality of life (HRQoL) were measured using questionnaires. Inclusion was terminated prematurely because reimbursement was suspended. RESULTS: A total of 213 patients (46.3% of intended number of patients) were randomized, of whom 209 were treated (105 in the MOCA group and 104 in the RFA group). Overall median pain scores during the first 14 days were lower after MOCA (0.2 vs 0.5 after RFA; P = .010), although the absolute difference was small. At 30 days, similar complication numbers (MOCA, n = 62; RFA, n = 63) and HRQoL scores (Aberdeen Varicose Vein Questionnaire: MOCA, 8.9; RFA, 7.6; P = .233) were observed. Hyperpigmentation was reported in seven patients in the MOCA group and two patients in the RFA group (P = .038). In the MOCA group, there were four complete failures (3.8%) compared with none in the RFA group (P = .045), although in one patient at 1 year, the vein showed occlusion. Median 30-day Venous Clinical Severity Score (VCSS) was significantly lower at 30 days after MOCA (1.0 vs 2.0 in the RFA group; P = .001), whereas VCSS was comparable at baseline (MOCA, 4.0; RFA, 5.0; P = .155). The 1- and 2-year anatomic success rate was lower after MOCA (83.5% and 80.0%) compared with RFA (94.2% and 88.3%; P = .025 and .066), mainly driven by partial recanalizations. After 2 years of follow-up, no differences were observed in the number of complete failures. Similar clinical success rates at 1 year (MOCA, 88.7%; RFA, 93.2%; P = .315) and 2 years (MOCA, 93.0%; RFA, 90.4%; P = .699) and no differences in HRQoL scores on the Aberdeen Varicose Vein Questionnaire at 1 year (MOCA, 7.5; RFA, 7.0; P = .753) and 2 years (MOCA, 5.0%; RFA, 4.8%; P = .573) were observed. There were two cardiac serious adverse events, a ventricular fibrillation in the MOCA group (1 year) and an unstable angina in the RFA group (2 years). One deep venous thrombosis occurred in the RFA group on 1-year duplex ultrasound, without clinical sequelae. CONCLUSIONS: Unilateral treatment with MOCA in the short term resulted in less postoperative pain but more hyperpigmentation compared with RFA and a faster improvement in VCSS. More anatomic failures were reported after MOCA, mostly driven by partial recanalizations, but both techniques were associated with similar clinical outcomes at 1 year and 2 years.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Holewijn S, van Eekeren RRJP, Vahl A, et al. Two-year results of a multicenter randomized controlled trial comparing Mechanochemical endovenous Ablation to RADiOfrequeNcy Ablation in the treatment of primary great saphenous vein incompetence (MARADONA trial). J Vasc Surg Venous Lymphat Disord. 2019. PMID: 31000063. doi:10.1016/j.jvsv.2018.12.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。